An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicullar Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis

被引：59

作者：

Ardeshna, Kirit M. ^{[1
]}

Qian, Wendi ^{[2
]}

Smith, Paul ^{[3
]}

Warden, June ^{[3
]}

Stevens, Lindsay ^{[3
]}

Pocock, Christopher F. E. ^{[4
]}

Miall, Fiona ^{[5
]}

Cunningham, David ^{[6
]}

Davies, John ^{[7
]}

Walewski, Jan ^{[8
,9
]}

Ferhanoglu, A. Burhan ^{[10
]}

Bradstock, Ken ^{[11
]}

Linch, David C. ^{[12
]}

机构：

[1] Univ Coll London Hosp, London, England

[2] MRC Clin, London, England

[3] Cancer Res UK & UCL Canc Trials Ctr, London, England

[4] Kent & Canterbury Hosp, Canterbury, England

[5] Leicester Royal Infirm, Leicester, Leics, England

[6] Royal Marsden Hosp, London SW3 6JJ, England

[7] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland

[8] Maria Sklodowska Curie Mem Inst Oncol, Warsaw, Poland

[9] Ctr Canc, Warsaw, Poland

[10] Nispetiye Mahallesi, Istanbul, Turkey

[11] Westmead Hosp, Sydney, NSW, Australia

[12] UCL, London, England

来源：

关键词：

D O I：

10.1182/blood.V116.21.6.6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5 / 5

页数：1